Ultragenyx Pharmaceutical Aktie
16,90
EUR
-2,80
EUR
-14,21
%
20,76
USD
+0,24
USD
+1,17
%
Werbung
Ultragenyx Pharmaceutical Aktie Analyse
| 11.05.18 | Ultragenyx Pharmaceutical overweight | Barclays Capital | |
| 21.02.18 | Ultragenyx Pharmaceutical Buy | Stifel, Nicolaus & Co., Inc. | |
| 05.12.17 | Ultragenyx Pharmaceutical Equal weight | Barclays Capital | |
| 14.09.17 | Ultragenyx Pharmaceutical Outperform | Wedbush Morgan Securities Inc. | |
| 08.08.17 | Ultragenyx Pharmaceutical Neutral | H.C. Wainwright & Co. | |
| 19.04.17 | Ultragenyx Pharmaceutical Neutral | Wedbush Morgan Securities Inc. | |
| 19.04.17 | Ultragenyx Pharmaceutical Neutral | H.C. Wainwright & Co. |
Werbung
Werbung